| [1] Alexandrakis M G, Passam F H, Kyriakou D S, et al. Pleural effusions in hematologic malignancies[J]. Chest, 2004, 125(4): 1546-1555.[2] Masellis-Smith A, Belch A R, Mant M J, et al. Hyaluronan-dependent motility of B cells and leukemic plasma cells in blood, but not of bone marrow plasma cells, in multiple myeloma: alternate use of receptor for hyaluronan-mediated motility (RHAMM) and CD44[J]. Blood,1996, 87(5):1891-1899.[3] Raci-Wetherbee E, Dincer H E. IgG myeloma presenting as a large mediastinal mass and pleural effusion[J]. J Bronchology Interv Pulmonol,2012, 19(1):65-67.[4] Kamble R, Wilson C S, Fassas A, et al. Malignant pleural effusion of multiple myeloma: prognostic factors and outcome[J]. Leuk Lymphoma,2005, 46(8):1137-1142.[5] 肖萌, 何娟,李艳,等.BD方案与VAD方案治疗多发性骨髓瘤的疗效比较[J].中国医科大学学报,2011,40(4):352-356.[6] Sonneveld P, Goldschmidt H, Rosiñol L, et al. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase Ⅲ randomized, controlled trials[J]. J Clin Oncol,2013, 31(26):3279-3287.[7] Zeng Z, Lin J, Chen J. Bortezomib for patients with previously untreated multiple myeloma: a systematic review and meta-analysis of randomized controlled trials[J]. Ann Hematol,2013, 92(7):935-943.[8] 燕玮,胡文旭,杨威. 万珂周疗方案对多发性骨髓瘤的疗效及安全性的Meta分析[J].现代肿瘤医学,2013,21(1):152-155. |
